8-KEarnings & ResultsExhibits & Filings

PFIZER INC 8-K Report, Financial Results (Apr 20, 2007)

Filed April 20, 2007For Securities:PFE

Summary

Pfizer Inc. filed a Form 8-K on April 20, 2007, to report its financial results for the first quarter of 2007. This filing primarily consists of a press release announcing these results, which is incorporated by reference as Exhibit 99. While the 8-K itself does not contain detailed financial statements or narrative analysis, it serves as a formal notification to investors and the market about the company's performance during the reported quarter. Investors should refer to the press release (Exhibit 99) for the specific financial figures, including revenue, earnings per share, and any commentary provided by Pfizer's management on business performance, trends, and outlook. This information is crucial for understanding the company's current financial health and its trajectory moving forward.

Key Highlights

  • 1Pfizer Inc. announced its first quarter 2007 financial results on April 20, 2007.
  • 2The primary content of the 8-K filing is a press release detailing these Q1 2007 results.
  • 3The press release is incorporated by reference as Exhibit 99 to the Form 8-K.
  • 4This filing serves as an official notification of the company's financial performance for the period.
  • 5Investors are directed to the Exhibit 99 press release for detailed financial information and management commentary.

Frequently Asked Questions

The main purpose of this 8-K filing by Pfizer Inc. is to officially announce and report its financial results for the first quarter of 2007 to the public and the SEC. It incorporates by reference the detailed press release that contains these results.

The actual financial results for Pfizer's first quarter of 2007 are detailed in the press release filed as Exhibit 99 to this 8-K. Investors should consult this press release for specific figures and management's commentary on performance.

This 8-K filing itself does not contain forward-looking guidance. Such information would typically be found within the press release (Exhibit 99) that is incorporated by reference. Investors should review that document for any commentary on future outlook.